These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

318 related articles for article (PubMed ID: 23385975)

  • 1. Lessons from in-vivo models of castration-resistant prostate cancer.
    Lin D; Gout PW; Wang Y
    Curr Opin Urol; 2013 May; 23(3):214-9. PubMed ID: 23385975
    [TBL] [Abstract][Full Text] [Related]  

  • 2. New agents and strategies for the hormonal treatment of castration-resistant prostate cancer.
    Sharifi N
    Expert Opin Investig Drugs; 2010 Jul; 19(7):837-46. PubMed ID: 20524793
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Androgen annihilation as a new therapeutic paradigm in advanced prostate cancer.
    Rove KO; Crawford ED
    Curr Opin Urol; 2013 May; 23(3):208-13. PubMed ID: 23492838
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Key targets of hormonal treatment of prostate cancer. Part 1: the androgen receptor and steroidogenic pathways.
    Vis AN; Schröder FH
    BJU Int; 2009 Aug; 104(4):438-48. PubMed ID: 19558559
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Novel agents for the management of castration-resistant prostate cancer.
    Haddad H; Garcia JA
    Curr Opin Urol; 2012 May; 22(3):175-82. PubMed ID: 22472509
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Emerging therapies in metastatic castration-sensitive and castration-resistant prostate cancer.
    MacVicar GR; Hussain MH
    Curr Opin Oncol; 2013 May; 25(3):252-60. PubMed ID: 23511665
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Novel chemotherapies in development for management of castration-resistant prostate cancer.
    Tewari AK; George DJ
    Curr Opin Urol; 2013 May; 23(3):220-9. PubMed ID: 23511791
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Overcoming castration resistance in prostate cancer.
    Tsao CK; Small AC; Galsky MD; Oh WK
    Curr Opin Urol; 2012 May; 22(3):167-74. PubMed ID: 22472508
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Androgen receptor targeting drugs in castration-resistant prostate cancer and mechanisms of resistance.
    Crona DJ; Milowsky MI; Whang YE
    Clin Pharmacol Ther; 2015 Dec; 98(6):582-9. PubMed ID: 26331358
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Molecular biology of castration-resistant prostate cancer: basis for the novel therapeutic targets.
    Mellado B; Marin Aguilera M; Pereira MV
    Arch Esp Urol; 2013 Jun; 66(5):453-62. PubMed ID: 23793763
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Castration-resistant prostate cancer: adaptive responses in the androgen axis.
    Egan A; Dong Y; Zhang H; Qi Y; Balk SP; Sartor O
    Cancer Treat Rev; 2014 Apr; 40(3):426-33. PubMed ID: 24139549
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Understanding the mechanisms of androgen deprivation resistance in prostate cancer at the molecular level.
    Karantanos T; Evans CP; Tombal B; Thompson TC; Montironi R; Isaacs WB
    Eur Urol; 2015 Mar; 67(3):470-9. PubMed ID: 25306226
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Genomic strategy for targeting therapy in castration-resistant prostate cancer.
    Mendiratta P; Mostaghel E; Guinney J; Tewari AK; Porrello A; Barry WT; Nelson PS; Febbo PG
    J Clin Oncol; 2009 Apr; 27(12):2022-9. PubMed ID: 19289629
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Androgen receptor (AR) aberrations in castration-resistant prostate cancer.
    Waltering KK; Urbanucci A; Visakorpi T
    Mol Cell Endocrinol; 2012 Sep; 360(1-2):38-43. PubMed ID: 22245783
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Castration induces up-regulation of intratumoral androgen biosynthesis and androgen receptor expression in an orthotopic VCaP human prostate cancer xenograft model.
    Knuuttila M; Yatkin E; Kallio J; Savolainen S; Laajala TD; Aittokallio T; Oksala R; Häkkinen M; Keski-Rahkonen P; Auriola S; Poutanen M; Mäkelä S
    Am J Pathol; 2014 Aug; 184(8):2163-73. PubMed ID: 24949550
    [TBL] [Abstract][Full Text] [Related]  

  • 16. The androgen/androgen receptor axis in prostate cancer.
    Bluemn EG; Nelson PS
    Curr Opin Oncol; 2012 May; 24(3):251-7. PubMed ID: 22327838
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Targeting the androgen receptor signalling axis in castration-resistant prostate cancer (CRPC).
    Tsao CK; Galsky MD; Small AC; Yee T; Oh WK
    BJU Int; 2012 Dec; 110(11):1580-8. PubMed ID: 22985411
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Androgen receptor (AR) expression in prostate cancer and progression of the tumor: Lessons from cell lines, animal models and human specimens.
    Tamburrino L; Salvianti F; Marchiani S; Pinzani P; Nesi G; Serni S; Forti G; Baldi E
    Steroids; 2012 Aug; 77(10):996-1001. PubMed ID: 22289337
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Novel strategies in the treatment of castration-resistant prostate cancer (Review).
    Marech I; Vacca A; Ranieri G; Gnoni A; Dammacco F
    Int J Oncol; 2012 May; 40(5):1313-20. PubMed ID: 22322981
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Biological properties of androgen receptor pure antagonist for treatment of castration-resistant prostate cancer: optimization from lead compound to CH5137291.
    Kawata H; Arai S; Nakagawa T; Ishikura N; Nishimoto A; Yoshino H; Shiraishi T; Tachibana K; Nakamura R; Sato H
    Prostate; 2011 Sep; 71(12):1344-56. PubMed ID: 21308717
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 16.